Skip to content
  • Contact Us
  • Request Samples
  • Order
Mill Creek Life Sciences
  • Our Technology
    • Human Platelet Lysate
    • Applications
    • Dendritic Cell Vaccine
  • Products
    • PLTMax®
    • PLTGold®
    • Order
    • Request Samples
  • Support
    • Technical Support
    • Publications
    • Posters
    • Distributors
    • FAQs
    • Contact Us
  • About Us
    • Our Company
    • Quality
    • News
    • Collaborate
    • Careers
Filters (2)
Filters
  • Reset all ×
  • Tumor cells ×

2 resources found

Show (2)
Cancel

Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma (Jun 2022)

p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status (Jun 2017)

MillCreekLifeSciences_StackedWhite-01

221 1st Avenue SW, Suite 209 Rochester, Minnesota 55902, USA

Phone: 507-287-6257
Fax: 507-289-2066
Email: info@millcreekls.com

OUR TECHNOLOGY

Human Platelet Lysate

Applications

Dendritic Cell Vaccine

PRODUCTS

PLTMax®

PLTGold®

Order

Request Samples

SUPPORT

Technical Support

Publications

Posters

Distributors

FAQs

Contact Us

ABOUT US

Our Company

Quality

News

Collaborate

Careers